Spruce Biosciences Announces Board and Executive Changes
Ticker: SPRB · Form: 8-K · Filed: Dec 12, 2025 · CIK: 1683553
| Field | Detail |
|---|---|
| Company | Spruce Biosciences, Inc. (SPRB) |
| Form Type | 8-K |
| Filed Date | Dec 12, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $104.13, $106.09, $108.00, $1,506.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, compensation, board-of-directors
Related Tickers: SPRB
TL;DR
Spruce Biosciences reshuffled its board and exec comp. Big changes coming?
AI Summary
Spruce Biosciences, Inc. announced on December 11, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for key personnel. Specific details regarding the individuals involved and the financial implications of these changes are outlined within the report.
Why It Matters
Changes in a company's board and executive compensation can signal shifts in strategy, governance, or financial outlook, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Board and executive changes can indicate underlying issues or strategic shifts that may impact the company's future performance and stock price.
Key Numbers
- 2025-12-11 — Date of Report (Earliest event reported)
- 001-39594 — SEC File Number (Spruce Biosciences' SEC filing number)
Key Players & Entities
- Spruce Biosciences, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- South San Francisco, California (location) — Principal Executive Offices
FAQ
Who are the specific directors or officers departing from Spruce Biosciences?
The filing indicates the departure of certain officers and directors, but the specific names are not listed in the provided text excerpt. Further details would be in the full document.
What are the key changes in compensatory arrangements for officers?
The filing mentions updates to compensatory arrangements for certain officers, but the specific details of these changes are not provided in the excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on December 11, 2025.
What is the primary business of Spruce Biosciences, Inc.?
Spruce Biosciences, Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.
Where are Spruce Biosciences, Inc.'s principal executive offices located?
The principal executive offices are located at 611 Gateway Boulevard, Suite 740, South San Francisco, California, 94080.
Filing Stats: 1,003 words · 4 min read · ~3 pages · Grade level 14.1 · Accepted 2025-12-12 16:03:50
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share SPRB Nasdaq Capital Marke
- $104.13 — e Plan (the "2020 Plan") was reduced to $104.13 per share (the "Reduced Exercise Price"
- $106.09 — rcise price per share that was at least $106.09 per share, which was one hundred and tw
- $108.00 — iously had exercise prices ranging from $108.00 to $1,506.00 per share. The Repriced
- $1,506.00 — exercise prices ranging from $108.00 to $1,506.00 per share. The Repriced Options inclu
- $344.25 — PH Chief Executive Officer 11,666 $344.25 Samir Gharib President and Chief Fi
- $122.65 — t and Chief Financial Officer 6,131 $122.65 to $1,506.00 The Board approved the O
Filing Documents
- sprb-20251211.htm (8-K) — 60KB
- 0001193125-25-317532.txt ( ) — 178KB
- sprb-20251211.xsd (EX-101.SCH) — 32KB
- sprb-20251211_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Spruce Biosciences, Inc. Date: December 12, 2025 By: /s/ Samir Gharib Samir Gharib President and Chief Financial Officer